Oligonucleotide CDMO Market (2026-2036)
The global Oligonucleotide CDMO (Contract Development and Manufacturing Organization) market is estimated to be USD 2.98 billion in 2026. This market is expected to reach USD 8.499 billion by 2036, growing at a CAGR of 11.05% during the forecast period.
- Published
- Jun 2026
- Pages
- 274
- Format
- PDF + Excel
- Report ID
- MR-2092
- Base year
- 2025
- 2026 · ESTIMATED
- $2.98B
- 2036
- $8.50B
- CAGR 2026–2036
- 11.05%
2025 baseline · 2026–2036 forecast at 11.05% CAGR · hover a bar for the value
Key highlights
The global Oligonucleotide CDMO (Contract Development and Manufacturing Organization) market is estimated to be USD 2.98 billion in 2026.
This market is expected to reach USD 8.499 billion by 2036, growing at a CAGR of 11.05% during the forecast period.
Analysis by Service Type: Contract Manufacturing Dominating the Landscape
Analysis by Oligonucleotide Type: Antisense Oligonucleotides (ASOs) Leading the Way
North America is expected to hold the largest share of the global Oligonucleotide CDMO market. This dominance is attributed to a highly developed biopharmaceutical industry, significant R&D investments in nucleic acid therapeutics, the presence of numerous key market players and research institutions, and a robust regulatory framework that supports drug development.
Europe is expected to hold a significant share of the global Oligonucleotide CDMO market, driven by a well-established pharmaceutical sector, strong academic research ecosystems, and increasing government support for biotechnology and life sciences.
Asia-Pacific is projected to witness the fastest CAGR during the forecast period. This rapid growth is driven by improving healthcare infrastructure, increasing investments in biopharmaceutical manufacturing capabilities, a growing pool of skilled scientific talent, and the rising demand for cost-effective CDMO services in countries like China, India, and South Korea.
Latin America is anticipated to witness steady growth in the Oligonucleotide CDMO market, primarily due to increasing investments in biopharmaceutical R&D, a rising focus on local drug manufacturing, and growing awareness about advanced therapeutic modalities in countries like Brazil and Mexico.
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2036 |
| Market Size (2026) | USD 2.98 billion |
| Market Size (2036) | USD 8.50 billion |
| CAGR (2026–2036) | 11.05% |
| Format | PDF, Excel & Cloud Portal · 274 pages |
| Segments Covered | By Service Type · By Oligonucleotide Type · By Application · By End User |
Report overview
Segments covered: service type, oligonucleotide type, application, end user.
The growth of this market is primarily driven by the burgeoning pipeline of oligonucleotide-based therapeutics, the increasing demand for specialized manufacturing expertise, and the strategic outsourcing by pharmaceutical and biotechnology companies to streamline drug development and production.
Oligonucleotide CDMOs are specialized contract organizations that provide comprehensive services for the development, synthesis, purification, analytical testing, and GMP-compliant manufacturing of oligonucleotides. These short strands of nucleic acids (DNA or RNA) are rapidly emerging as a powerful class of therapeutics, offering novel approaches to treat a wide range of diseases, including genetic disorders, cancer, and infectious diseases. According to the International Agency for Research on Cancer, approximately 20 million new cancer cases were diagnosed globally in 2022, with the number projected to increase to more than 35 million by 2050, highlighting the growing need for next-generation precision therapeutics such as oligonucleotide-based medicines. As the complexity and regulatory requirements for oligonucleotide drugs increase, pharmaceutical and biotechnology companies are increasingly relying on the specialized expertise and infrastructure of CDMOs to navigate the intricate journey from discovery to commercialization.
The oligonucleotide CDMO market plays a pivotal role in accelerating the translation of scientific breakthroughs into life-saving medicines. These organizations offer critical capabilities such as custom synthesis, process development, scale-up, quality control, and regulatory support, enabling clients to overcome manufacturing challenges, reduce costs, and expedite time-to-market. According to the American Society of Gene & Cell Therapy, more than 4,000 cell, gene, and RNA-based therapies were in active development globally in 2024, reflecting the rapid expansion of advanced therapeutics that increasingly rely on specialized CDMO manufacturing capabilities. The market's expansion is intrinsically linked to the success of oligonucleotide therapeutics, which are gaining significant traction due to their high specificity, diverse mechanisms of action, and potential to address previously untreatable conditions.
Report infographic
Market dynamics
17 factors across 5 forcesBurgeoning Pipeline of Oligonucleotide-Based Therapeutics: The
increasing number of oligonucleotide drugs in preclinical and clinical development, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers, is creating a significant demand for specialized CDMO services for their synthesis and manufacturing.
Increasing Outsourcing by Pharmaceutical and Biotechnology
Companies: To manage the complexities of oligonucleotide manufacturing, reduce capital expenditure, and leverage specialized expertise, pharmaceutical and biotechnology companies are increasingly outsourcing their development and manufacturing needs to CDMOs, driving market growth.
Technological Advancements in Oligonucleotide Synthesis and
Purification: Continuous innovations in oligonucleotide synthesis technologies (e.g., solid-phase synthesis, liquid-phase synthesis) and purification techniques (e.g., HPLC, tangential flow filtration) are improving efficiency, purity, and yield, making large-scale production more feasible and cost-effective.
Growing Investment in Gene Therapy and
RNA-Based Medicines: The rapid progress and significant investments in gene therapy and other RNA-based therapeutic modalities are fueling the demand for high-quality, GMP-grade oligonucleotides, which are essential building blocks for these advanced therapies.
Table of contents
12 chapters · 119 sections · 274 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Service Type | Analysis by Service Type: Contract Manufacturing | Contract development |
| By Oligonucleotide Type | Antisense Oligonucleotides (ASOs) | Small interfering RNA (siRNA) |
| By Application | Therapeutics | Diagnostics |
| By End User | Pharmaceutical & biopharmaceutical companies | Academic & research institutes |
By Service Type
- Analysis by Service Type: Contract Manufacturing Dominating the Landscape
- The contract manufacturing segment is expected to hold the largest share of the global oligonucleotide CDMO market.
- This dominance is attributed to the high capital investment required for specialized manufacturing facilities, the need for GMP compliance, and the technical expertise demanded for large-scale oligonucleotide production, making outsourcing a strategic choice for many companies.
- The contract development segment is anticipated to witness the fastest CAGR, driven by the increasing complexity of novel oligonucleotide designs and the growing need for specialized process development and analytical method development support.
By Oligonucleotide Type
- Analysis by Oligonucleotide Type: Antisense Oligonucleotides (ASOs) Leading the Way
- Antisense Oligonucleotides (ASOs) are expected to command the largest share of the global oligonucleotide CDMO market.
- ASOs have a well-established therapeutic history and a robust pipeline, driving consistent demand for their synthesis and manufacturing.
- The small interfering RNA (siRNA) segment is anticipated to exhibit the fastest CAGR, propelled by the significant advancements in RNA interference technology and the increasing number of siRNA-based therapeutics entering clinical trials.
By Application
- Analysis by Application: Therapeutics at the Forefront
- The therapeutics segment is projected to account for the largest share of the oligonucleotide CDMO market.
- This is due to the rapidly expanding pipeline and commercialization of oligonucleotide drugs for various diseases, driving the demand for GMP-compliant manufacturing services.
- The diagnostics segment is expected to grow at the fastest CAGR, fueled by the increasing use of oligonucleotides in molecular diagnostics, PCR-based assays, and genetic testing.
By End User
- Analysis by End User: Pharmaceutical & Biopharmaceutical Companies as Key Clients
- Pharmaceutical & biopharmaceutical companies are expected to command the largest share of the global oligonucleotide CDMO market.
- These companies are the primary developers and commercializers of oligonucleotide therapeutics, driving the bulk of outsourcing demand for specialized CDMO services.
- The academic & research institutes segment is anticipated to exhibit the fastest CAGR, driven by the increasing funding for basic research in nucleic acid biology and the growing need for custom oligonucleotide synthesis for discovery and preclinical studies.
Geographic analysis
North America
Largest shareNorth America is expected to hold the largest share of the global Oligonucleotide CDMO market. This dominance is attributed to a highly developed biopharmaceutical industry, significant R&D investments in nucleic acid therapeutics, the presence of numerous key market players and research institutions, and a robust regulatory framework that supports drug development. The United States, in particular, is a major contributor due to its large patient population and strong funding for biotechnology research. North America: A Global Leader in Biopharmaceutical Innovation
Europe
Europe is expected to hold a significant share of the global Oligonucleotide CDMO market, driven by a well-established pharmaceutical sector, strong academic research ecosystems, and increasing government support for biotechnology and life sciences. Countries like Germany, the U.K., and Switzerland are key contributors due to their advanced research capabilities and the presence of leading CDMOs. The key companies operating in the European market are Lonza Group AG, AGC Biologics, and CordenPharma International. Europe: Advancing Nucleic Acid Drug Development with Strong Research Ecosystems
Asia-Pacific
Fastest growthAsia-Pacific is projected to witness the fastest CAGR during the forecast period. This rapid growth is driven by improving healthcare infrastructure, increasing investments in biopharmaceutical manufacturing capabilities, a growing pool of skilled scientific talent, and the rising demand for cost-effective CDMO services in countries like China, India, and South Korea. Government initiatives to promote biotechnology and attract foreign investment also contribute to the region's market expansion. The key companies operating in the Asia-Pacific market are WuXi AppTec, Samsung Biologics, and GenScript Biotech Corporation. Asia-Pacific: Rapid Growth Fueled by Expanding Biopharmaceutical Manufacturing
Latin America
Latin America is anticipated to witness steady growth in the Oligonucleotide CDMO market, primarily due to increasing investments in biopharmaceutical R&D, a rising focus on local drug manufacturing, and growing awareness about advanced therapeutic modalities in countries like Brazil and Mexico. The modernization of healthcare facilities and the adoption of international quality standards also contribute to the demand for CDMO services. The key companies operating in the Latin American market are Thermo Fisher Scientific Inc. (with regional presence) and Merck KGaA (with regional presence). Latin America: Emerging Opportunities in Biopharmaceutical Outsourcing
Middle East & Africa
The Middle East & Africa region is expected to experience gradual growth in the Oligonucleotide CDMO market, driven by increasing healthcare investments, government initiatives to develop local biopharmaceutical industries, and a growing focus on adopting advanced medical technologies. Countries like UAE and Saudi Arabia are investing in biotechnology research and manufacturing, leading to a gradual increase in demand for CDMO services. The key companies operating in the Middle East & Africa market are Thermo Fisher Scientific Inc. (with regional presence) and Merck KGaA (with regional presence). Middle East & Africa: Gradual Expansion with Developing Biopharma Sector
Competitive landscape
The global Oligonucleotide CDMO market is characterized by a dynamic and highly competitive landscape. It features a mix of large, integrated CDMOs, specialized oligonucleotide manufacturers, and contract research organizations (CROs) offering synthesis services. Key players are focusing on expanding their manufacturing capacity, investing in advanced synthesis and purification technologies, offering integrated end-to-end solutions, and forming strategic partnerships or acquisitions to strengthen their market positions. The competitive strategy often revolves around demonstrating technical expertise, ensuring regulatory compliance, providing high-quality GMP-grade materials, and offering flexible and cost-effective solutions to clients. Companies are also investing heavily in R&D to develop novel chemistries and processes for next-generation oligonucleotide therapeutics.
Frequently asked questions
The global Oligonucleotide CDMO market is estimated at USD 2.98 billion in 2026 and is projected to reach USD 8.499 billion by 2036, growing at a CAGR of 11.05%.
Cite this report
Meticulous Research. (2026). Oligonucleotide CDMO Market - Global Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MR-2092). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/oligonucleotide-cdmo-market-6775